menu
    • menu
    [{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentiva \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zentiva \/ Undisclosed"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine reuptake||Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zentiva","amount2":5.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":5.5,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Zentiva \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Zentiva","sponsor":"GTCR","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Zentiva \/ GTCR","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ GTCR"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Cinclus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zentiva","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"10","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Tillomed Laboratories Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"MALTA","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"}]

    Find Clinical Drug Pipeline Developments & Deals by Prague Scientific

    Menu

    Prague Scientific

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : GTCR

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Zentiva Announces Sale from Advent to GTCR

                            Details : GTCR’s acquisition of Zentiva includes its portfolio, ongoing R&D, and pipeline, continuing the company’s expansion of generics and development projects in Europe.

                            Product Name : Affenid XL

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 11, 2025

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : GTCR

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : $5,500.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aurobindo Pharma closing in on $5.5b Zentiva buyout

                            Details : Zentiva holds a broad portfolio of generic and biosimilar products, including Affenid XL (methylphenidate hydrochloride) for the treatment of Attention-Deficit/Hyperactivity Disorder.

                            Product Name : Affenid XL

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 20, 2025

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : $5,500.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Cinclus Pharma

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Zentiva Inks €220M Deal for Former AstraZeneca GI Drug in Europe

                            Details : Under the licensing agreement, Zentiva will hold the rights for the commercialization and manufacturing of linaprazan glurate, in Europe.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $14.7 million

                            May 22, 2025

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Cinclus Pharma

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raltegravir Potassium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Generic HIV raltegravir medicines approved

                            Details : Raltegravir is an approved, small molecule, HIV-1 integrase inhibitor, available as a film coated tablet for the treatment of HIV in adult and paediatric patients weighing at least 40kg.

                            Product Name : Raltegravir-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Raltegravir Potassium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Biocon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biocon to Obtain Approval for Diabetes Drug, Liraglutide in UK

                            Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

                            Product Name : Liraglutide-Generic

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 28, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Biocon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Prague Scientific

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Convenient Treatment Option for Thromboembolic Events

                            Details : Rivaroxaban oral suspension, inhibits free FXa and prothrombinase activity. It has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, it decreases thrombin generation.

                            Product Name : Rivaroxaban-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2023

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Recipient : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology

                            Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Tillomed Laboratories Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Zentiva Completes Major Product Acquisition from Tillomed Spain

                            Details : Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 16, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Tillomed Laboratories Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Prague Scientific

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zent2U Announces Successful Pivotal Bioequivalence Study Results on Omeprazole Immediate Release Capsules

                            Details : Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid...

                            Product Name : Omeprazole Magnesium-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 25, 2022

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Biocon Limited Enters Into a Commercialization Agreement With Zentiva in Europe

                            Details : Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.

                            Product Name : Liraglutide-Generic

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth